Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Morgan Stanley Alpha ex-100 Conference 2025
25 slides from Proteomics International Laboratories's conference presentation, Apr 8, 2025
Slide 1: Investor Presentation Morgan Stanley Alpha ex-100 Conference
ASX Release 8 April 2025 ASX code: PIQ Investor Presentation Morgan Stanley Alpha ex-100 Conference Proteomics International Laboratories Ltd (Proteomics International; the Company; ASX: PIQ), a pioneer in precision diagnostics, is pleased to announce its Managing Director Dr Richard Lipscombe and C
Slide 2: Proteomics International Morgan Stanley Alpha ex-100 Conference
ASX: PIQ Proteomics International LABORATORIES LTD Morgan Stanley Alpha ex-100 Conference Investor Presentation 8 April 2025 Dr Richard Lipscombe Philip Prather Managing Director Chief Commercial Officer 1
Slide 3: Disclaimer
Disclaimer ASX: PIQ This Presentation is provided by Proteomics International Laboratories Ltd (Proteomics International, Proteomics, the Company, ASX: PIQ). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in
Slide 4: Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd ASX: PIQ A medical technology company at the forefront of precision diagnostics Launching four first-in-class tests driven by a proprietary platform technology: • A novel and accurate blood test for predicting the onset of chronic kidney disease in type 2 an
Slide 5: Corporate Overview
Corporate Overview ASX: PIQ Financial and Corporate Corporate Snapshot ASX code PIQ • Top 40 Shareholders hold 41% Market Capitalisation A$55m Cash (31 Dec 2024) A$5.3m • Directors are highly aligned with shareholders holding 13% Share Price (4 April 2025) A$0.42 • Revenue generating Shares on issue
Slide 6: Board of Directors
Board of Directors ASX: PIQ Dr James Williams PhD (Melbourne), MBA (UWA), BSc, Hons (Aberdeen), GAICD, Non-Executive Chair Accomplished manager, director, scientist and investor with experience covering all aspects of life-science technology translation. Involved from startup to commercialisation, i
Slide 7: Commercialisation Team
Commercialisation Team ASX: PIQ Dedicated team responsible for driving commercial adoption Phillip Prather Jacqueline Gray Chief Commercial Officer Chief Financial Officer & Head of Corporate Development Phillip brings extensive leadership in the global medical devices Jacqueline has held senior lea
Slide 8: Go-to-Market optionality: Synergistic pathways
Go-to-Market optionality: Synergistic pathways ASX: PIQ Initial sales led by Direct to Consumer with option to expand through licencing Direct to consumer (DTC) and digital marketing pathway PI Reference Blood collection engaged and PI receives payment Laboratories samples run Telehealth consult: Pr
Slide 9: Go-to-Market
Go-to-Market ASX: PIQ Direct to Consumer (DTC) digital solution implemented • Launched in Australia in Q1 CY25 ➢ Automated immunoassay established ➢ Clinical ISO 15189 certification pending ➢ Blood collection logistics established ➢ GP practices engaged ➢ Integrated digital solution enacted 8
Slide 10: Patient journey & Revenue capture model
Patient journey & Revenue capture model ASX: PIQ Managed via a fully integrated digital solution @ www.myTEST.health @ Consumer Browsing diabetes/ Keyword SEM Patient Patient kidney health Online advert Payment Gateway GP provides test results to patient campaign White Label Test Website & guides cl
Slide 11: GP blast followed by relationship nurture workflows
GP blast followed by relationship nurture workflows ASX: PIQ Comprehensive Customer Relationship Management (CRM) system established A blood test which can identify the onset of chronic kidney disease up to four years before clinical symptoms appear GP Requests eDetail ProD GP Requests eDetail ProEs
Slide 12: Market launch: Australia and USA
Market launch: Australia and USA ASX: PIQ Australia USA ISO 17025 established PI Reference Laboratory CLIA certification established ISO 15189 pending PromarkerD: 84,000 pa PromarkerD: 84,000 pa Initial capacity of laboratory PromarkerEso: 32,000 pa PromarkerEso: 32,000 pa PromarkerD: Q1 CY25 Promar
Slide 13: Market launch: strategic rationale
Market launch: strategic rationale ASX: PIQ The Direct to Consumer route provides maximum optionality: ➢ Fastest and most cost-effective path to market ➢ Scalable with low cost of customer acquisition compared to traditional sales model ➢ Provides a platform to: ▪ partner with virtual care providers
Slide 14: Multiple Value Drivers in H1 CY25
Multiple Value Drivers in H1 CY25 ASX: PIQ Q4 Q1 Q2 Milestone TARGET Qtr CY24 CY25 CY25 Impact Commercial US reference lab established ✓ Key to first US sales and reimbursement First Sales PromarkerD in USA Initiate pathway to significant revenues Australian clinical lab established ✓ PromarkerD lau
Slide 15: Summary – Exceptional Growth Opportunity
ASX: PIQ • Disruptive, cutting-edge technology & proven in-house Summary – diagnostics platform • Multiple patented tests Exceptional • PromarkerD test de-risked, patented, commercial launch Growth ready Opportunity • PromarkerEso, PromarkerEndo and OxiDx tests nearing market entry • Tests are scala
Slide 16: Contact
Contact ASX: PIQ Dr Richard Lipscombe Dirk van Dissel Managing Director Investor Relations T: +61 8 9389 1992 Candour Advisory E: enquiries@proteomicsinternational.com T: +61 408 326 367 www.proteomicsinternational.com E: dirk@candouradvisory.com.au ASX:PIQ 15
Slide 17: Supplemental – the Promarker suite of diagnostic tests
Supplemental – the Promarker® suite of diagnostic tests 16
Slide 18: The Need: Target Populations for DKD, Endo and Eso
The Need: Target Populations for DKD, Endo and Eso ASX: PIQ Targeting initially the US and Australian markets, with EU and other jurisdictions to follow 10.5% of the global adult population have diabetes 1 in 9 women have endometriosis 10-20% western populations have Gastroesophageal reflux disease
Slide 19: PromarkerD: Diabetic Kidney Disease
PromarkerD: Diabetic Kidney Disease ASX: PIQ Intellectual Property Patents granted in all major jurisdictions - PromarkerD Patent family & Trademark covers 72% of the world’s diabetes patients CE Mark (EU) registration received for the PromarkerD Immunoassay IVD Regulatory US sales utilising Lab Dev
Slide 20: My impression on PromarkerD market release
My impression on Promarker®D market release ASX: PIQ What are our Key Opinion Leaders saying? "When kidney function is lost, it is lost forever. Identifying people at increased risk of developing impaired kidney function before this function is irreversibly gone is the best way to protect their kidn
Slide 21: PromarkerEso: Esophageal Cancer
PromarkerEso: Esophageal Cancer ASX: PIQ First-in-class blood test ‘PromarkerEso’ ready for commercialisation Clinical question – can a blood test distinguish between individuals who are: 1) healthy 2) esophageal adenocarcinoma (EAC) patients ➢ Only 50% of EAC patients report chronic acid reflux (GE
Slide 22: My impression on PromarkerEso market release
My impression on Promarker®Eso market release ASX: PIQ What are our Key Opinion Leaders saying? “As a pathologist, I am keenly aware of the multitude of problems and limitations we have regarding detection of esophageal cancer and its precursors based on tissue analysis. Proteomic biomarker serum an
Slide 23: PromarkerEndo: Endometriosis
PromarkerEndo: Endometriosis ASX: PIQ First-in-class blood test ‘PromarkerEndo’ nearing commercialisation Clinical question – can a blood test distinguish between individuals who are: 1) healthy 2) symptomatic patients (pelvic pain but surgically-diagnosed absence of endometriosis) 3) endometriosis
Slide 24: OxiDx: Oxidative Stress
OxiDx: Oxidative Stress ASX: PIQ Groundbreaking blood test nearing commercialisation What is Oxidative Stress? Targeting commercial use of OxiDx technology: • Oxidative stress occurs when the body’s ➢ Athletic monitoring tool for competition preparedness: antioxidant defences are overwhelmed by an o
Slide 25: Proteomics International (Est'd 2001)
Proteomics International (Est’d 2001) ASX: PIQ ASX:PIQ Identity Proteomics International is a medical technology company specialising in predictive diagnostics and advanced analytical services using proteomics – the industrial scale study of the structure and function of proteins. Mission To improve
Proteomics International Laboratories — Morgan Stanley Alpha ex-100 Conference 2025 on 6ix